Cost-effectiveness Analysis of Rivaroxaban versus Acenocoumarol in the Prevention of Stroke in Patients with Non-valvular Atrial Fibrillation in Spain

Cost-effectiveness Analysis of Rivaroxaban versus Acenocoumarol in the Prevention of Stroke in Patients with Non-valvular Atrial Fibrillation in Spain

# Objective The aim of this study was to evaluate, from the Spanish National Health System perspective, the cost-effectiveness of rivaroxaban (20 mg/day) versus use of acenocoumarol (5 mg/day) for the treatment of patients with non-valvular atrial fibrillation (NVAF) at moderate to high risk for str...

Full description

Saved in:
Bibliographic Details
Main Authors: Carlos Rubio-Terrés, Ruth Graefenhain de Codes, Darío Rubio-Rodríguez, Thomas Evers, Santiago Grau Cerrato
Format: Article
Language:English
Published: Columbia Data Analytics, LLC 2016-02-01
Series:Journal of Health Economics and Outcomes Research
Online Access:https://doi.org/10.36469/9823
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items